The European paediatric Soft Tissue Sarcoma Study Group (EpSSG; https://www.epssgassociation.it/) is holding its winter meeting on November 29th – December 1st, 2023, in Barcelona, Spain.
Being committed to the development of essential medicines for rare pediatric cancers, ORPHELIA Pharma is proud to support this event as a sponsor.
EpSSG Association exists to promote and manage clinical trials, encourage and facilitate clinical and basic science research, foster optimal standards of care, organize educational meetings for its members and other professionals, and advocate for patients with soft tissue sarcoma (STS). STS account for approximately 8% of all pediatric cancers. They are divided into two main groups : rhabdomyosarcoma (approximately 60% of STS in children) and non-rhabdomyosarcoma soft tissue sarcomas (this includes a large number of different tumor types which together account for about 40% of STS). Additional information about this event can be found here : https://www.epssgassociation.it/activities/epssg-meetings/upcoming-meeting/winter-meeting/,229
